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INTRODUCTION 
Cervix  is  the  most  common  site  in  the female  genital  tract  
which  is  exposed  to  viral and  bacterial  infections.  Also  it  is  the  
target  for carcinogenic  agents  leading  to  invasive  cancer.  
 Cervical   carcinoma  is  the  second  most  common  malignancy  
in women  according   to  the  worldwide  cancer  statistics.
 1
 Patients  
with  invasive  cancer cervix  has  an  average  age  of  45  years.
 2
  Every  
year, almost  50%  of  the  reported   new  cases   have  been  proved  to  
be  fatal. The  tumor  occurs  most  often  in  the  older  age  groups  but  
also  occurs,  with  relatively  increased  frequency  in  young  females.
3
 
The  decline  in  the  rate  of cancer  cervix  are  due  to  the  effective  
screening  programmes  via  papanicolaou  smear.
 2,68
 
Routine   cytological  PAP  smear screening, early diagnosis  and 
curative  treatment  had  reduced  the  mortality of  cancer cervix. 
All  the  features which  are  of  diagnostic  and  prognostic  
significance  cannot  be  revealed  by  routine  histological  techniques.             
80%  of  the  cases  are  of  squamous  cell  carcinoma  subtype.  The  
next  most  common  is  Adenocarcinoma  constituting  15%.  Remaining  
5%  of  the  cases  are  contributed  by  Adenosquamous  and 
 2 
 
Neuroendocrine    carcinomas.  Most  of  the  histological  subtypes  are  
associated  with  high  risk  Human  Papilloma  viruses.
4
  
Studies  have  shown  that  there  is  a  crucial  role  for  high  risk  
Human  papilloma  viruses  in  the  etiology  of  carcinoma  cervix.
 5
   
Host  immune  response  factors  contribute  to  the  persistent  HPV  
infection  and  progression  to  cervical  neoplasia ( Cervical  
Intraepithelial  Neoplasia  and  Invasive  cancer). Genes  in  the  Human  
Leukocyte  region  of  chromosome  6  are  associated  increased  
susceptibility  to  transforming  properties  of  high  risk  HPV. 
Cancer  cells  have   many  mechanisms  to  escape  from  immune  
mediated  recognition  and  destruction.  Loss  of  cell   surface  
expression  of  Human  Leukocyte  Antigen ( HLA )  class I  molecules  
is  very  important  particularly,  as  this  enables  cancer  cells  to  evade  
recognition  and  lysis  by  cytotoxic ( CD 8 + ) T lymphocytes.
 12,61
  
Present  study  intends  to  analyse  the  clinical  features  and  
histomorphology  of  cancer  cervix and  to assess  the expression  of  
HLA I and  CD 8  in  the  differentiated  forms  of  malignant  lesions  of  
the  cervix.  Also  to  correlate  the  grade  of  malignancy  and  HLA 1  
and  CD8  expression  in  carcinoma  cervix. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM AND OBJECTIVES 
 
 3 
 
 
AIM AND OBJECTIVES OF THE STUDY 
1. To  analyse  the  clinical  features  and  histomorphology  of  
carcinoma  cervix. 
2. To  assess  the  expression  of  Human  Leukocyte  Antigen 1  and  
CD 8  in  the  differentiated  forms  of   malignant  lesions  of  the  
cervix. 
3. To  correlate  the  grade  of  malignancy  and   HLA 1  and  CD 8 
expression  in  carcinoma  cervix. 
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REVIEW OF LITERATURE 
ANATOMY 
Cervix  is  a  portion  which  is  located  at  the lower  end of 
uterus. It connects the cavity of uterus to the vagina. A narrow cervical 
canal passes through it.  
Ectocervix is the external surface of the vaginal portion and 
endocervix is related to the endocervical canal of cervix. The internal os 
is the upper limit of the endocervical canal. 
3
The external os is the 
opening of endocervical canal into vagina.
  4
 
HISTOLOGY 
           The endocervical  glands  are  lined  by the  mucinous  epithelium. 
The  columnar  epithelium  changes  abruptly  into  a  non  keratinizing   
stratified squamous epithelium at the portio vaginalis. Lamina propria   
connective tissue is more fibrous than in the uterus. Blood vessels, 
nerves, smooth muscles and elastic tissue are also seen. Smooth muscle  
fibres are mainly located  in the endocervix. The sphincteric action of  
isthmus is due to concentric arrangement of smooth  muscles  constituting   
about  50 to 60%  of the supporting tissue. 
 5 
 
        Majority of the ectocervix is covered  by  non  keratinizing  stratified 
squamous epithelium which in child  bearing  age  is  composed  of  basal  
cell, mid zone and superficial layers. The stem cells of cervical  
squamous  mucosa  are  located  in  the  suprabasal  layer  as proposed  by  
some authors
3
. The mucus secreting columnar cells rest on an  
inconspicuous subcolumnar reserve cell which is located  at  or  near  the  
squamo-columnar junction. This is involved primarily in squamous   
metaplasia, cervical  intraepithelial neoplasia  and  malignancy
 4
. 
INFLAMMATORY CONDITIONS 
INFECTIONS 
The common organisms include bacteria, virus, fungi, parasites  
and protozoa. Infections are frequently due to Candida albicans, 
Trichomonas  vaginalis, Gardnerella  vaginalis, HPV and HSV. 
The infectious viral agents which  cause  morphological  alterations  
of cells have a site of  predeliction  for  squamous  epithelium  of  cervix. 
Anogenital  HPV  infections  are  transmitted  by  direct  skin -to -  skin  
or  mucosa - to - mucosa  contact. Both  squamous  and  glandular  
lesions are associated  with  high  risk  HPV  infections
 4
.    Inflammatory  
infiltrates are lymphocytes, plasma cells and histiocytes in chronic  
cervicitis. 
 6 
 
Atypical morphological changes due to inflammation is difficult to 
differentiate from  genuine  atypia. But  the  changes  are  mild  without  
increase  in  mitosis  or  reduction  in  cytoplasm. 
REGENERATING  EPITHELIUM 
Chronic persistent infection can lead to reactive changes in the 
epithelium due to cervical erosion. This is also found in epithelial injury 
due to biopsy or conization. The changes include disorganization in 
epithelium and nuclear atypia in ectocervix and  endocervix. 
Cytologically and histologically, these morphological changes mimics 
intra epithelial neoplasia. The nuclei are in uniform size and shape, 
clumped chromatin  with normal mitotic figures and cytoplasmic 
membrane is well defined. 
ATROPHY
6 
             Hormone deficiency causes changes in maturation of squamous 
epithelium  in  pre pubertal, peri menopausal and post menopausal states. 
The changes are  uniform basal and para basal cells with increased 
nuclear cytoplasmic ratio, coarse chromatin and rare mitosis. These  
epithelial changes  are  sometimes  difficult  from  that  of  squamous  
intraepithelial  neoplasia. 
 7 
 
 THERAPY RELATED ATROPHY: 
Radiation therapy in the treatment of cancer cervix may cause 
morphological changes in glandular and squamous epithelium which can 
be acute or chronic inflammation and there will be varying degrees of 
atypia and enlarged nuclei without mitotic figures. Stroma will be 
showing fibrosis, atypical fibroblasts and multinucleated cells. 
CERVICAL CANCER SCREENING AND PREVENTION: 
Cytologic  cancer  screening  has  significantly  reduced  mortality  
from  cancer  cervix
 2
.  The  reason  for  which  the  cytological  screening  
is more  effective  is  that  most  carcinomas  arise  from  precursor  
lesions  over  the course  of  years.  These lesions  shed  atypical  cells  
which  can  be  detected  on cytological  examination.  With  a  spatula  or  
brush,  the  transformation  zone  of  the  cervix  is  scraped  
circumferentially  and  the  cells   are  spun  down  or  smeared  onto  a  
slide.  After  fixation  and  staining  by  Papanicolaou method,  the  
smears  are  screened  microscopically
 
.  
Testing  for  HPV  DNA  in  the  cervical  scrape  is  a  molecular  
method  of cancer  cervix  screening 
2
.  It  has  a  higher  sensitivity but  
lower  specificity  as  compared  to  Pap  smear  test.  HPV  DNA  testing  
 8 
 
may  be  added  to  Pap  test  for  screening  in  women  of  30  years  of 
age and  above. 
MALIGNANT LESIONS OF CERVIX 
PRECANCEROUS CONDITIONS 
SQUAMOUS  INTRA EPITHELIAL LESION 
           Squamous Intraepithelial lesion (SIL) occurs in the squamous 
epithelium which is the zone of epithelial transformation. Zone  of  
transformation is the region between original and functional 
squamocolumnar  junction.  It is the area of  ectropion  also.  As  it  is 
dynamic, it is very susceptible to changing  hormonal  and  environmental  
influences. 
This  is  the  area  most  susceptible  to  Human  Papilloma virus  
infection with  higher  susceptibility  of  the  immature  squamous  
epithelium  to  infection. 
In 1975,  the WHO  for  the  first  time  proposed  a  terminology  
to  describe  and   report  precursor  lesions  of  carcinoma  cervix  in  
biopsies. 
 9 
 
Dysplasia was described as mild, moderate and severe  and   
carcinoma  in  situ is a distinct entity  composed  of  atypical  cells  in  the  
entire  squamous  epithelium. 
In the 1980s, ISGYP--International  Society  of  Gynaecological  
Pathologist  introduced  a  terminology  which  have  replaced  dysplasia 
with Cervical  Intraepithelial  Neoplasia ( CIN )  and  have  eliminated  
carcinoma  in  situ.  The  CIN  was  divided  into  1, 2  and  3  with  
carcinoma  in  situ being  included  into  the  Cervical  Intraepithelial  
Neoplasia III. 
The  Bethesda  system  of  reporting  cervical  cytology  is  recently  
applied  for  reporting  of  cervical  lesions. 
 4
 
It  is  a  two-tiered  system  which  divides  dysplasia  into  Low  
grade Squamous Intraepithelial Lesions (LSIL) and High grade  
Intraepithelial  Lesions (HSIL ). 
      The single category of HSIL includes both CIN 2 and CIN 3.  The  
Bethesda  includes  Condyloma  acuminatum  into  LSIL,  whereas  
WHO  kept  it as  a  seperate  entity. 
The  Bethesda  system  of  classification  unifies  the  terminologies 
used  for  both  cervical  cytology  and  biopsy  reporting
  7
. 
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In  2014  Bethesda  system, atypical squamous  cells  are  
continued to be included in the squamous cell abnormality with  
subcategorization as Atypical Squamous cells of Undetermined  
Significance ( ASC- US) and Atypical  Squamous  cells-  cannot  exclude  
a  High  grade  squamous  intraepithelial  lesion ( ASC- H). 
2014 Bethesda  update  maintains  the  two-tiered  reporting 
terminology  of  LSIL/  HSIL. 
INVASIVE CANCER CERVIX: 
Cervix  cancer is  the second  most  common form  of  neoplasm  in  
women  worldwide. 
1,8
  Statistics  of  cancer  mortality  states  that  after  
lung and  breast  cancer,  it  is  the  third  leading  cause  of death.  In  
Asian  women, the incidence  and mortality  rate  is  4 to  5 times  greater  
than  in   developed  nations.
 50
 
Squamous cell carcinoma is having two peaks of age distribution,  
one at 35  years  and  another  one  around  50  to  55  years. 
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AETIOLOGY: 
Age: 
The  single  most  important  factor  is  age  at  first  intercourse.
 3
 
Young  and  sexually  active  women  are  at  increased  risk  for  HPV  
infection  and  cervical  intraepithelial  neoplasia.  With  increasing  age,  
there  will  be  increased  risk  for  carcinoma.  Also  the  risk  decreases  
with  the  menopausal   approach. 
Religion and race:   
Jews  and  Muslim women have reduced  risk  of  carcinoma  
cervix because  of  the  ritual  circumcision  done  for  male  children. 
Social and Economic factors: 
        Carcinoma  cervix  is  more  common  in  people  of  low  socio  
economic status as they have poor sanitation,  early  and  frequent  coitus. 
Coitus: 
       It  is  4  to  5  times  more  common  in  sexually  active  women. 
 
 
 
 12 
 
Cervical Infection 
 
  
 
  Infection due to Human  Papilloma  Virus  plays  an  important  
role.  High  risk  HPV  types  16,  18,  31  and  45  accounts  for  more  
than  80%  of cancer cervix
2,9
 . HPV  16  is  the  most  common  type  and  
18  is  the  second  common  type
 20
. It  infects  epithelial  cells
 54
. 
There  are  around  15  to  20  types  acting  as  a  cofactor  in  the  
development  of  carcinoma. 
 
 
 
URR - UPSTREAM  
REGULATORY REGION 
ER - EARLY REGION 
LR - LATE REGION 
 
 
 
URR - UPSTREAM REGULATORY 
REGION 
E -  EARLY REGION 
L - LATE REGION 
HPV GENOME 
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Hormonal Factors: 
Oral contraceptives with oestrogen and progesterone favours 
intraepithelial lesions and also invasive cervical cancers
 6
. 
The  other  risk  factors  include  smoking,  pregnancy  at  an  early  
age,  HIV infection,  vitamin  deficiency. 
Predisposing  Histological  changes: 
      These  include  basal  cell  hyperplasia,  squamous  metaplasia  and  
High grade Squamous Intraepithelial Lesion are significant  precancerous  
conditions. 
Histological  classification  of  cervical  carcinoma: 
Carcinoma  cervix  starts  at  the  squamocolumnar  junction and  
80  to  90 % are  of  squamous  cell in  origin. 
Remaining 5 to 10% are of columnar cells in origin 
(Adenocarcinoma). This  is  more  in  young  women  who  are  smokers  
and  pill  users. 
The remainder  constitutes  the  mixed  types. 
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WHO CLASSIFICATION OF UTERINE CERVIX TUMORS (2014) 
Epithelial  tumors 
Squamous  cell  tumors  and  its  precursors 
Squamous  intraepithelial lesions 
Low - grade  squamous intraepithelial lesion 
High - grade  squamous intraepithelial lesion 
Squamous cell carcinoma, NOS 
Keratinizing 
Non - keratinizing 
Papillary 
Basaloid 
Warty 
Verrucous 
Squamotransitional 
Lymphoepithelioma - like carcinoma 
Benign  squamous  cell  lesions 
Squamous  metaplasia 
Condyloma  acuminatum 
Squamous papilloma 
Transitional metaplasia 
Glandular  tumors  and  its  precursors 
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Adenocarcinoma  in situ 
Adenocarcinoma 
Endocervical  adenocarcinoma , usual type 
Mucinous carcinoma ,NOS 
Gastric type 
Intestinal type 
Signet - ring cell type 
 Villoglandular  carcinoma 
 Endometrioid adenocarcinoma 
 Clear cell carcinoma 
 Serous carcinoma 
 Mesonephric carcinoma 
Adenocarcinoma  admixed  with  neuroendocrine carcinoma 
Benign  glandular  tumours and tumour - like lesions 
                    Endocervical  polyp 
                    Mullerian  papilloma 
                    Nabothian cyst 
Tunnel clusters 
Microglandular hyperplasia 
Lobular endocervical  glandular hyperplasia 
Diffuse  laminar  endocervical hyperplasia 
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Mesonephric remnants and hyperplasia 
Arias Stella reaction 
Endocervicosis 
Endometriosis 
Tuboendometrioid  metaplasia 
Ectopic prostate tissue 
Other epithelial tumours 
Adenosquamous carcinoma 
Glassy cell carcinoma 
Adenoid basal carcinoma 
Adenoid cystic carcinoma 
Undifferentiated carcinoma 
Neuroendocrine tumors 
Low  grade neuroendocrine  tumour  
                     Carcinoid  tumour 
                     Atypical  carcinoid  tumour 
       High - grade neuroendocrine  carcinoma 
                     Small  cell neuroendocrine  carcinoma 
                     Large  cell neuroendocrine  carcinoma 
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Mesenchymal  tumors  and  tumor- like lesions 
Benign 
      Leiomyoma 
      Rhabdomyoma 
      Others 
Malignant 
Leiomyosarcoma 
Rhabdomyosarcoma                       
Alveolar soft part sarcoma  
Angiosarcoma                                       
Malignant peripheral nerve sheath tumour 
Other sarcomas 
        Liposarcoma 
        Undifferentiated endocervical  carcinoma 
        Ewing  sarcoma 
Tumour - like lesions 
         Postoperative  spindle - cell nodule 
         Lymphoma - like lesion 
 
Mixed  epithelial  and  mesenchymal tumor 
 Adenomyoma 
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Adenosarcoma 
Carcinosarcoma 
Melanocytic tumors                  
Blue naevus 
Malignant melanoma 
Germ cell tumours 
Yolk sac tumour 
Lymphoid and  myeloid  tumors 
Lymphomas 
Myeloid neoplasms 
Secondary tumors 
Reagan et  al  found  three  groups  in  squamous  cell  carcinoma
10 
  
Non - Keratinizing - large  cell  type ( moderately  differentiated  grade ) 
Keratinizing - large cell type (well differentiated grade) 
Small cell Non - Keratinizing type (poorly differentiated grade)            
Other variants are  
Papillary squamo transitional carcinoma 
Verrucous carcinoma 
Lympho epithelioma like carcinoma 
Basaloid carcinoma   
Condylomatous (warty) carcinoma  
 19 
 
MICROINVASIVE SQUAMOUS CELL CARCINOMA: 
In 1847, Mestwerdt was the one to introduce about  microinvasive  
carcinoma.  It  is  a  type  of  carcinoma  which  can  be  diagnosed  only  
by  microscopical  examination. 
           Invasion  by  tumor  cells  extend  to a maximum  depth  of  5 mm  
and to a maximum width  of 7 mm. 
INVASIVE SQUAMOUS CELL CARCINOMA:  
            After  breast  carcinoma,  squamous  cell  carcinoma  of  cervix  is  
the  second  most  common  carcinoma  worldwide.  And  it  is  the  most  
common  carcinoma  in  the  women  of  developing  countries.
1
  
The  overall  frequency  has  been  decreased  because  of  the  
national cervical  screening  programmes.  This  has  also  been  used  in  
the detection  of  asymptomatic  small  and  early  invasive  lesions. 
Cervical  squamous  cell  carcinoma  has  three  variants
10, 21 
Non - Keratinizing  carcinoma  accounts  for  two  third  of  cases.  
It  shows  individual  cell  cytoplasmic  keratinization  and  intercellular  
bridges,  but
 
nesting  of   tumor  cells,  keratin  pearls  are  not  present.
 
 20 
 
Keratinizing carcinoma accounting for one sixth of cases. It  
contain keratin  pearls  and  nests  of  tumor  cells  with  central  keratin.  
Keratohyaline granules, intercellular bridges and cytoplasmic  
keratinization  are  also seen.  
 
Small cell non -keratinizing carcinoma are characterised  by  sheets  
of non - keratinizing  small  cells   with  high  nuclear  cytoplasmic  ratio.
 
Squamous  cell  (epidermoid)  carcinoma  constitutes  about  70% .  
The common  pattern  is  non - keratinizing  large  cell  type  with  better  
prognosis. 
Well differentiated keratinizing carcinoma accounts for 25% of the 
cases.  
Undifferentiated carcinoma is less common with poor prognosis. 
Based on the differentiation, modified Broder 's  method
11,23
 
includes 
                Well differentiated grade- Grade 1 
                Moderately differentiated grade- Grade 2 
                Poorly differentiated  grade-  Grade  3 
Grade  2  is  common,  then  grade 3  and  then  grade  1  are  
common  in  decreasing  order.  
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Basaloid carcinoma has basaloid appearance.  It is composed of  
nests of tumor cells with less amount of cytoplasm and peripheral  
palisading of  cells. 
Verrucous carcinoma  is  a  very  rare  subtype characterised  by  
exophytic growth  with  minimal  or  no  atypia. 
Warty carcinoma is also  exophytic with  koilocytic  changes  in  
the  surface epithelium. 
Papillary carcinoma is having papillary growth pattern. It is  
divided  into 
         1)  Papillary undifferentiated carcinoma 
         2)  Papillary transitional cell carcinoma 
         3)  Papillary squamo - transitional carcinoma 
Lymphoepithelial  like
1
 carcinoma is  characterised  by  
undifferentiated  cells  with lymphocytic  infiltration  in the  stroma and 
the neoplastic cells have  syncitial growth pattern, poorly defined cell 
borders and pale  eosinophilic cytoplasm. 
Adenocarinoma: 
Primary  adenocarcinoma  comprises  15%  of  all  carcinoma  
cervix. Its  incidence  is  on  the  rise  in  young  women.  Long  term  use  
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of  oral  contraceptives  and  its  association  with  endocervical  neoplasia  
has  been  reported.
3 
  
Most  common  pattern  is  well  differentiated  glandular  pattern  
with  mucin. 
Morphological  variants  of  adenocarinoma 
Endometrioid  adenocarcinoma 
Papillary  serous  carcinoma 
Adenosquamous ( mixed ) 
Adenoid  cystic  carcinoma 
Adenoid  basal carcinoma 
Clear  cell  carcinoma 
Endometrioid  adenocarcinoma  is  similar to  its  ovarian  and 
endometrial counterparts.  Its  incidence  is  increasing.  Minimal  
deviation  adenocarcinoma  is otherwise  known  as  adenoma  malignum. 
Glucksmann and  Cherry  emphasised  the  importance  of  
adenosquamous carcinoma and used  the  terminology of  mixed  
carcinoma.
4
 Mixed  carcinoma  includes  adenocarcinoma  with  well 
defined  squamous component. 
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 A  type  of  poorly  differentiated  adenosquamous  carcinoma  is  
Glassy cell  carcinoma  occuring  in  a  younger  age  group and   has  
been  associated  with  pregnancy. 
Clear  cell  carcinoma  or  mesonephric  carcinoma  is  composed  
of  cells  arranged  in  tubulo cystic,  papillary  pattern.  The  cells  will  
have  abundant  clear  cytoplasm,  enlarged  and  pleomorphic  nuclei  
which  protrudes  into  the  lumen  having  a  '  Hob  nail '  appearance. 
It  is  common  in  young  women   and  have a  relatively  good  
prognosis. 
Mixed  Epithelial /  Mesenchymal  neoplasm  includes 
1. Adenomyoma 
2. Carcinosarcoma 
3. Cervical  Adenosarcoma 
Adenosarcoma  is  a  biphasic  tumor. Primary  adenosarcoma  is  a  very  
rare ( 2% )  neoplasm  in  the  genital  tract. 
Melanocytic  tumors 
  1.  Blue  Nevus 
  2.  Malignant  melanoma 
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Malignant  melanoma  is  a  rare  neoplasm  of  which  only  30  cases  
have  been reported.  The  mean  age  is  60  years  and  it  is  having  
poor  prognosis. 
Neuroendocrine  tumors  include 
    Carcinoid 
    Atypical  carcinoid 
    Large  cell  neuroendocrine  carcinoma 
    Small  cell  neuroendocrine  carcinoma 
Carcinoid 
Benign tumors have a characteristic organoid pattern. The  
difference between  typical  and  atypical  carcinoid  includes  atypia  of  
the  nucleus  and   mitosis. 
Atypical  Carcinoid 
            Cytological  atypia,  areas  of  necrosis  and  increased  mitotic  
count ( around  5  to  10  per  high  power  field )  are  the  features  of  
atypical  carcinoid. 
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Small  cell  carcinoma 
             This  accounts  for  about  1 to  6% of  cervix  carcinoma.  
Glandular  or  squamous  component  may  be  seen  in association. 
Large  cell  neuroendocrine  carcinoma 
             This  is  composed  of  high  grade  neoplastic  cells  with  
abundant  cytoplasm,  vesicular  chromatin,  prominent  nucleoli  and  
high  mitosis  ( > 10 per  10  high  power  field ). 
             Undifferentiated  sarcoma,  metastasis  from  other  sites  and  
adenocarcinoma  with  neuroendocrine  differentiation  are  the  
differential  diagnosis and immunohistochemistry  markers  include  
neuron  specific  enolase,  synaptophysin  and  chromogranin  are useful 
to arrive at a diagnosis.   
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2009 MODIFICATION OF FIGO STAGING OF CARCINOMA OF 
THE CERVIX UTERI: 
STAGE I - Cervical carcinoma confined to the uterus (extension to the 
corpus should be disregarded) 
STAGE I A - Invasive carcinoma diagnosed only by microscopy; all 
macroscopically visible lesions , even with superficial  invasion, are stage 
IB 
STAGE IA1 - Stromal invasion no greater than 3.0 mm in depth and 7.0 
mm or less in horizontal spread 
STAGE IA2 - Stromal invasion more than 3.0 mm and not more than 5.0 
mm with a horizontal spread of 7.0 mm or less 
STAGE IB - Clinically visible lesion confined to the cervix or 
microscopic lesion greater than IA2 
STAGE IB1- Clinically visible lesion 4.0 cm or less in greatest dimension 
STAGE IB2 - Clinically visible lesion more than 4.0 cm in greatest 
dimension 
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STAGE II - Tumor invades beyond the uterus but not to pelvic wall or to 
lower third of the vagina 
STAGE IIA - Without parametrial invasion  
STAGE IIA 1 - Clinically visible lesion < or equals 4.0 cm in greatest 
dimension 
STAGE IIA 2 - Clinically visible lesion > 4.0 cm in greatest dimension 
STAGE II B - With parametrial invasion 
STAGE III - Tumor extends to the pelvic wall and /or involves lower 
third of vagina and /or causes hydronephrosis or nonfunctioning kidney 
STAGE IIIA - Tumor involves lower third of vagina with no extension to 
pelvic wall 
STAGE IIIB - Tumor extends to pelvic wall and/or causes 
hydronephrosis or nonfunctioning kidney 
STAGE IV - The carcinoma has extended beyond the true pelvis or has 
involved (biopsy proven) the mucosa of the bladder or rectum. A bullous 
edema , as such, does not permit a case to be allotted to stage IV 
STAGE IV A - Spread of the growth to adjacent organs 
STAGE IV B - Spread to distant organs. 
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IMMUNE SYSTEM: 
The immune   system is the specific  defense  mechanism.
 24
  It  
comprises  of  humoral immune system (B cell mediated) and cell 
mediated immune system (T cell mediated).
13
   Both  the   systems  are  
responsible  for  elimination  of  a  virus  and  virus  induced  lesions.   
Immunological  surviellance  is  performed  by  CTLs  which  are  
CD8 + T lymphocytes,which destroy tumor cells expressing HLA class 1 
molecules over their surface.
14
    HLA class 1 molecules  are  virtually  
expressed  on  all  cells.   
The  Major  Histocompatability  Complex ( MHC ) or Human 
Leukocyte Antigen (HLA)  is  located  on the short  arm  of  chromosome  
6  at  6p21.3  and  comprises  about  240  different  gene  loci  of  which  
may encode  for  HLA  molecules.
15,25.
  The  MHC  can   be  subdivided  
into  three closely  related  families - Class 1 (  the  classical  1A  genes,  
HLA- A,  -B,  and-C  and  the  non  classical  1B  genes,  HLA- E, -H, -G  
and  -F ) ,  Class  2 (HLA- DR, -DP  and  - DQ  genes ),  Class 3 ( 
includes  genes  encoding complement  and  tumor  necrosis  factor ).  
The  HLA  class 1  and  2  molecules are  encoded  by  HLA -  Class  1  
and  2  genes  respectively.  On  each  chromosome  6,  the  genes  in  the  
class  1  to  3  regions  compose  a combination  which  is  called  a  
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haplotype.  The  two  haplotypes  on  the  chromosome  6  pair  combined  
are  called  the  HLA  genotype.   
The   HLA  genotype  is  expressed  as HLA  Class  1  and  2 
molecules   on  the  cell  surface and  this  is  called  the  HLA  
phenotype. 
The  endogenously  processed  antigens  (tumor  or  viral  
associated products)  are  processed  and  presented  to the  circulating  
cytotoxic  T  lymphocytes. 
ROLE OF CD 8 IN CANCER CERVIX: 
The  cervix  has  the  largest   concentration  of  lymphocytes  in  
the  female  genital  tract.  Also  as  a  component  of  mucosal  immune  
system, T lymphocytes  guards  against  the  ascending  infection  from  
the  vagina.  Two  populations  of  T  cells  have specific  cytotoxicity  
against  virus  infected  cells : the  CD  4  expressing  T  helper  cell (T h)  
which  is  restricted  to  MHC  class 2 expressing  targets  and  the  CD  8  
expressing  cytotoxic /  suppressor  T  cell ( T c/s )  which  is  MHC  class  
1  restricted
  16
.  The  CD  8  cells  are  believed  to  be  the  principal  
effectors  against  HPV  infected  epithelium  and  epithelial  tumors. 
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IMMUNE EVASION IN CANCER CERVIX 
Loss  of  HLA  class  1  cell  surface  expression  occurs  in  cancer 
cervix.
 26
 In  1976,  the  first  description  of  MHC  class 1  loss  was 
done  in  a mouse  model (Gardener  Lymphoma )  in  Dr. Festenstein  
laboratory.   It  is  thought  to  result  in  escape  from  the  cytotoxic  CTL  
attack.  It  is  caused predominantly  by  losses  at  chromosome  6p21.3 ,  
the  region  where  the  HLA genes  are  localised. Loss of  heterozygosity 
(haplotype  loss )  is  the  most  frequent  alteration  of  class 1  
expression.
 12,27
  This  is  caused  by  various  defects  in  HLA  genomic  
region  including  chromosomal  dysfunction,  mitotic recombination  and  
genetic  conversion.  The  accurate  detection  of  HLA complex  on  
tumor  cell  surface  is  fundamental  as  it  predetermines  the tumor  cell  
recognition  by  both  cytotoxic  T  lymphocytes  and  NK  cells.
 28
 
Tumor  cells  with  complete  HLA  loss  are  not   recognised  by  
CTL  but  NK cells   able  to  target  them   for  elimination.  Tumors  
with  partial  loss  may evade  both  NK  cell  as  well  as  T  cell  
mediated  immune   surviellance.             
   Ekaterina  S. Jordanova  et  al
9
  studied  Human  Leukocyte  
Antigen  class 1  chain  related  molecule  A  and  CD 8+ / Regulatory  T 
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cell ratio: Which variable  determines  survival  of  cervical  cancer  
patients ? 
           They  have  concluded  Weak  HLA- A  expression  combined  
with  low CD  8+  ratio reveals a patient  group  with  the  poorest  
survival  in  cancer cervix.  As  a single  variable , low CD 8+ / Treg               
( regulatory  T  cell )  was  a significant  independant   unfavourable  
prognostic  factor. 
    
N. Aptisiauri  et  al.,
12
  MHC  class  1  antigens  in  malignant  cells:  
Immune  escape  and  response  to  immunotherapy.  Expression  of  HLA  
class  1  alterations  in  tumor  cells  is  a  key  factor  to  be  considered  
during  selection  of  immunotherapy  strategy  and  is  a  biomarker  to be  
monitored  during  treatment.
 12,29
         
   Akash  M  Mehta  et  al 
15
 studied  association  of  antigen  processing 
machinery and  HLA class 1  defects  with clinicopathological  outcome  
in  cervical  carcinoma. 
             A  complete  understanding  of  the  mechanisms  and  relevance  
of  HLA class 1  downregulation  and  immune  evasion  may  contribute  
to  the  rational design  of  tumor  vaccines   and  T  cell  based 
immunotherapies. 
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     Jiang  Tao  Fan  et  al
16
  studied  the  expression  of HLA- 1, CD 8  
and  CD 4  and   their  clinical  significance  in  cervical  cancer. 
It  showed  the  expression  of  HLA-1, CD 8 and  CD 4  are  
downregulated or  deleted  in  CIN  and  cervical  cancer  and  they  may  
play  important  roles  in  the  development  and  progression  of  CIN  to 
invasive cancer. 
           M J Arends  et al 
17
 studied  the  aetiology,  pathogenesis  and  
pathology  of  cervical  neoplasia. 
           Swati  Patel  and  Shubhada  Chiplunkar 
18
studied  the  host  
immune  responses  to  cervical  cancer. 
            It showed  the  HPV  uses  different  strategies to  evade  immune   
recognition.  Understanding  the  immune evasion  mechanisms  used  by  
HPV  will  help  in  designing  newer  therapeutic  strategies for  cervical  
cancer. 
            
 
Robert P Edwards  et  al
19
  studied  T  lymphocytes  infiltrating  
advanced  grades  of  cervical  neoplasia. 
The  invasive  lesion  and  its  association  with  CD 8  T cells  
locally strongly  suggests  that  the  immune  response  is  a  clinical  
cofactor  in  the  progression  of  cervical  neoplasia. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
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                              MATERIALS AND METHODS 
Study design 
                      Prospective study 
Study period 
                     July 2016 to July 2017 
Study place 
                    Coimbatore Medical  College  Hospital,  Coimbatore. 
Sample  size 
                  A total number of 30 cases. From  case  records  brief  clinical  
data  were  collected , which  included  age,  clinical  diagnosis  and  
surgical  procedure. 
The  following  inclusion  and   exclusion  criteria  were adopted. 
Inclusion  criteria: 
1. Hysterectomy  and  small  cervical  biopsy  specimens  with   
cervical  cancer. 
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2. Patients  in  all age  groups ( 20 - 60 years ) of  abnormal  uterine  
bleeding  with  suspected  carcinoma  cervix. 
3. VIA / VILI  positive  cases. 
Exclusion criteria: 
1. Inadequate  specimens. 
2.  Chronic  cervicitis. 
3. Squamous  Intraepithelial  Lesion. 
4.  In  Treated  patients  before surgery. 
5. Specimen  not  sent  in  formalin. 
Methods: 
Among  the  total  cases  received in  the  Department  of  
Pathology  in our  hospital  during  the  study  period,  30  cases were  
taken  into  study  as  per  inclusion  criteria  and  further  evaluated. 
             All  those  30 small  biopsies  and  hysterectomy  specimens  are  
selected , then  fixed  in  10%  formalin,  embedded  in  paraffin   and  
stained  with  hematoxylin  and  eosin. 
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HEMATOXYLIN AND EOSIN STAINING: 
REAGENTS USED: 
1. Hematoxylin  solution - Ehrlich' s  Hematoxylin 
2. Eosin  1%   solution 
3. Acid  alcohol  1%  solution 
PROCEDURE: 
1. Deparaffinize  the  sections  by  immersion  in  xylene  for  30  
seconds. 
2. Then  place  the  sections  in  isopropyl  alcohol  for  15  minutes. 
3. Wash  then  in  running  tap  water. 
4. Stain  for 10  to  15  minutes  in  Ehrlich's  hematoxylin. 
5. Differentiation  with  1%  acid  alcohol  is  done  two  to  three  
dips. 
6. Blueing  for  10  minutes  is  carried  out. 
7. Counterstain with  Eosin 1%  solution  three  to  four  dips. 
8. Wash in running tap water done. 
9. Air dried. 
10. Mounting with  DPX  done. 
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IMMUNOHISTOCHEMISTRY 
METHOD 
            Two step indirect technique 
PRINCIPLES OF THE PROCEDURE 
Using  a  two  stage  processes ,  antigens  were  detected  in  cells  
and tissues.  The  first  was  the  binding  to  specific  epitopes  of  the  
primary  antibody.  Second  was  a  calorimetric  reaction  to  detect  the  
bindings.   
Sections  of  the  tissues  were  fixed  and  attached  to  the  coated  
slides. 
The  paraffin  embedded  sections  were  then  dewaxed.  Antigen  
retrieval  was done.  This  consists  of  treating  the  formalin  fixed  
sections  in  a  microwave oven  in  an  aqueous  solution.  It  recovered  
full  antigenicity  with  most  of  the  antibodies.  These  also  included  
cases  which  were  formerly  unreactive  with formalin  fixed  tissue.  
Subsequently , the  tissue  sections  were  treated  with  Peroxide  block  
and  Power  block  for  blocking  of  endogenous  peroxidases  and  non  
specific  protein-  protein  interactions ,  respectively. 
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REAGENTS USED: 
1. Peroxide block : 3%  Hydrogen  peroxide  in  water 
2.  Power  block  reagent :  A  highly  effective  universal  protein  
blocking reagent.  It  contains  casein  and  propriety  additives  in  
PBS  with  15 mM  sodium  azide. 
3. Chromogen :  DAB-  Diaminobenzidine. 
4.  Liquid  DAB  substrate :  comprises  Tris- buffer  containing   the  
peroxide  and  stabilizer. 
5. Super enhancer reagent. 
6. Poly- HRP reagent. 
7. Counter stain:  Ehrlich' s  hematoxylin. 
BUFFER  SOLUTIONS: 
TRIS  BUFFER (  pH - 7.6 ) : 
Tris buffer salt : 0. 605 gms 
Sodium  chloride : 8 gms 
Distilled  water :  1000 ml 
1 N Hydrochloric  acid : 3 ml 
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CITRATE BUFFER (pH -6.0): 
            Trisodium  citrate : 2.94 gms 
            Distilled water : 1000 ml 
            1 N Hydrochloric  acid : 5 ml 
TRIS - EDTA (pH -9.0 ): 
             Tris buffer salt : 6.05 gms 
             Disodium   EDTA: 0. 744 gm 
             Distilled water :  1000  ml 
PROCEDURE :  
1. Sections  are deparaffinised  with  xylene  for  30  minutes  as  2  
changes  15  minutes  each. 
2. Sections   are  dehydrated  in  absolute  alcohol  for  5  minutes 
with  2 changes. 
3. Sections  are  washed  in  tap  water for  10  minutes. 
4.  Slides  are  then  rinsed  in  distilled water for  5 minutes. 
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5. Antigen  retrieval  is  done  by  placing  the  slides with  
appropriate  buffer  solution  in  microwave :  medium  
temperature  - 10  minutes,  high  temperature -10 minutes. 
6. They  are  then  cooled  to  room  temperature and  then  rinsed  in   
distilled water. 
7. Sections  are  then   washed  in  TBS  buffer  for  5  minutes  with  
2  changes. 
8. Then  the  slides  are  treated  with  Peroxide  block  for  10  
minutes. 
9. Sections  are again washed  in  TBS  buffer  for  5  minutes  with  
2  changes. 
10. Treated  with  Power  block  for  10  minutes. 
11. Slides  are  then  drained   and  covered  with  primary  antibody  
for  2  hours. 
12. Wash  in  TBS  buffer for  5  minutes  with  2  changes. 
13. Sections  are  then  covered  with  super  enhancer  for  30  
minutes. 
14. Wash  in  TBS  buffer  for 5  minutes  with  2  changes. 
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15. Poly -  HRP  reagent  was  applied  and  left  for  30  minutes. 
16. Wash  in  TBS  buffer  for  5  minutes  with  2  changes. 
17. Treat  with  DAB  chromogen  with  substrate  buffer  for  5  to  8  
minutes. 
18. Wash  in  TBS  buffer  for  5  minutes  with  2  changes. 
19. They are then washed in tap water for 5 minutes. 
20. Sections  are  then  counterstained  with  Ehrlich's   hematoxylin  
for  30  seconds. 
21.  Wash  in  tap  water  for  5 minutes. 
22.  Slides  are  then  air  dried  and  mounted  with  DPX. 
Tumor  cells  were  scored  positive  if  there  was  golden  brown  
membranous,  cytoplasmic  or  nuclear  staining  in  the   neoplastic  cells. 
  Negative  diagnosis  was  obtained  when  no  golden  brown  
staining  was  observed. 
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Interpretation  of  IHC: 
HLA - 1: 
Positive staining refers  to cytoplasmic  or  cytoplasmic  membrane  
staining   of  cells
 16
.  Intensity  of   positive  staining  is  graded  between  
0  to  3+. 
CD 8: 
Positive staining  refers  to  staining  of  cytoplasm  or  cytoplasmic  
membrane
 16
. Intensity  of  positive  staining   is  graded  between  0  to  
3+  as below : 
Sl. 
No 
Grading 
Percentage  of  cells  
expressing HLA - 1 and  
CD 8 positivity 
1.     0 ( negative )  No positively staining cells  
2.     1+ ( focally positive ) 
 < 25 % of positively 
staining cells 
3.     2+ ( positive ) 
 25 - 50 % of positively 
staining cells 
4.     3+ ( diffusely positive ) 
 > 50 % of positively 
staining cells 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION AND RESULTS 
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OBSERVATION AND RESULTS 
Of  2542  gynaecological  specimens  received  at  Pathology 
Department  Coimbatore  Medical  College  Hospital  during  the  period  
of  August  2016 - July  2017,  malignancy  was  reported  in  215  cases 
(8.45 %). 
This  prospective  study  included  routinely  processed  biopsies  
from 30  patients  with  malignant   lesions  of  the  cervix  diagnosed  
histologically during   the  period  of  August  2016 - July  2017. 
AGE INCIDENCE: 
              The  patients  diagnosed  as  cervical  carcinoma  were  divided  
into  6  groups   according  to  age  i.e  31 -  40 , 41 - 50 , 51 - 60 , 61 - 70 
, > 71 years  of  age.   
        The  age  wise  distribution  of  cervical  cancer  is  given  in  the  
following  Table  1  and  Chart 1. 
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TABLE 1 
AGE WISE DISTRIBUTION OF CANCER CERVIX CASES 
AGE GROUP NO. OF CASES PERCENTAGE (%) 
31 – 40 1 3.3 
41 – 50 12 40 
51 – 60 8 26.7 
61 – 70 10 33.3 
> 71 1 3.3 
TOTAL 30 100 
 
There was increased incidence of cervical cancer observed in the  
age group of 41- 50 years (40 %) followed by 51-60 years (26.7%) and  
61 - 70 years (26.7 %). 
CHART 1 
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The  following  table  2  and  chart  2  shows  the  colposcopic 
findings  in  carcinoma  cervix  cases  clinically :   
TABLE 2 
COLPOSCOPY FINDINGS IN CANCER CERVIX CASES 
FINDINGS NO. OF CASES PERCENTAGE (%) 
ViA / ViLI + 9 30 
GROWTH 14 46.7 
ULCERATION 4 13.3 
EROSION 3 10 
TOTAL 30 100 
 
CHART 2 
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It  includes  ViA /  ViLI  ( Visual  inspection  with  Acetic  acid  
and visual  inspection with Lugol ' s  Iodine ), clinically  obvious  growth,  
cervical  ulceration  and  erosion  cases.  Most common clinical finding 
was growth (46.7%). 
The  following  Table  3  and  Chart  3  shows   the  type  of  
carcinoma  cervix  cases  diagnosed  histologically  as  Squamous  cell  
carcinoma,  Adenocarcinoma,  Adenosquamous  carcinoma  and  Clear  
cell  carcinoma.  
                                              TABLE 3 
TYPE OF CARCINOMA CERVIX CASES 
TYPE NO.OF CASES PERCENTAGE 
SCC- Well differentiated 9 30% 
SCC- Moderately 
differentiated 
8 26.7% 
SCC- Poorly differentiated 7 23.3% 
Adenocarcinoma 2 6.7% 
Adenosquamous carcinoma 3 10% 
Clear cell Ca 1 3.3% 
TOTAL 30 100% 
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CHART 3 
TYPES OF CARCINOMA CERVIX CASES  
 
 
                                     
   Squamous  cell  carcinoma  is  the  most  common  type  constituting  
80%  followed  by  Adenosquamous carcinoma  and  Adenocarcinoma. 
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 Table  4  and  Chart  4 includes  the  various  histopathological  features  
seen  in  Squamous  cell  carcinoma. 
                                                  TABLE 4 
HISTOPATHOLOGICAL FEATURES OF SCC 
FEATURES NO.OF CASES 
Large cell type 11 
Small cell type 13 
Keratinizing type 10 
Non - Keratinizing type 14 
Keratin pearls 9 
Surrounding desmoplasia 7 
Surrounding Inflammation 8 
Mitotic activity 9 
Tissue Eosinophilia 8 
Presence of Necrosis 6 
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CHART 4 
 
 
Non keratinizing  and small cell types are the common features that 
are identified. These types are seen in both moderately differentiated as 
well as poorly differentiated squamous cell carcinoma. 
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Table  5 and  Chart  5 includes  the  histopathological  features   
seen  in  other  types  of   carcinoma  cervix. 
                                                   TABLE 5 
HISTOPATHOLOGICAL FEATURES OF OTHER TYPES OF 
CARCINOMA CERVIX 
FEATURES NO.OF CASES 
Glandular pattern 2 
Presence of Mucin 1 
Presence of clear cells 1 
Presence of Hob nail cells 1 
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CHART 5 
 
  
Glandular pattern and the presence of mucin are observed in 
Adenocarcinoma. Clear cells and Hob nail cells are observed in Clear cell 
carcinoma.  
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The  following  Table  6  and  Chart  6  shows  the  expression  of  HLA 1  
in different  grades  of  carcinoma   cervix .    
TABLE 6 
EXPRESSION OF HLA - 1 IN SQUAMOUS CELL CARCINOMA 
TYPE 1+ (< 25%) 2+(25 -50%) 3+(>50%) 
SCC - Well 
differentiated 
carcinoma 
            2          2         5 
SCC- Moderately 
differentiated 
carcinoma 
            4          2         2 
SCC-Poorly 
differentiated 
carcinoma 
            5          1         1 
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CHART 6 
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HLA 1 expression with less intensity is observed in 2 well differentiated 
and 5 poorly differentiated SCC. The intensity is more in 7 well 
differentiated  and  2 poorly differentiated SCC. 
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The  following  Table  7  and  Chart  7  shows  the  distribution  of   
HLA 1 in  different  grades  of   Squamous  cell   carcinoma  of  cervix. 
                                                    TABLE 7 
DISTRIBUTION OF HLA 1 IN SCC CERVIX 
 TYPE  1+ (negative) 2+& 3+(positive) TOTAL 
SCC - Well 
differentiated 
carcinoma 
2 7 9 
SCC- Moderately 
differentiated 
carcinoma 
4 4 8 
SCC-Poorly 
differentiated 
carcinoma 
5 2 7 
TOTAL 11 13 24 
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CHART 7 
 
According  to  this ,  the  positive  expression  of  HLA 1  is  seen  
in  9 out  of  24 squamous cell carcinoma  cases  which  are  of  well  
differentiated  grade.  It  is  negative  in  7 out  of  24 SCC  cases  which  
are  of  poorly  differentiated  grade. It is  positive  in  4 out  of  8  
moderately  differentiated  grade  of  Squamous  cell  carcinoma. 
 
 
 
 
 
0
1
2
3
4
5
6
7
WELL 
DIFFERENTIATED
MODERATELY 
DIFFERENTIATED
POORLY 
DIFFERENTIATED
2
4
5
7
4
2
DISTRIBUTION OF HLA 1 IN SQUAMOUS CELL 
CARCINOMA
1+ POSITIVE
2+ & 3+ NEGATIVE
 55 
 
The  following  Table  8  and  Chart  8  shows  the  distribution  of  
HLA 1 in   other  types  of  Carcinoma  cervix. 
TABLE 8 
DISTRIBUTION OF HLA 1 IN OTHER TYPES OF CARCINOMA 
CERVIX 
TYPE 1+ (Negative) 2+& 3+( Positive ) 
Adenocarcinoma 2 1 
Adenosquamous 
carcinoma 
1 1 
Clear cell carcinoma 1 0 
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The  following  Table  9  and  Chart  9  shows  the  expression  of  
CD 8  in  different  grades  of  Squamous  cell  carcinoma  cervix. 
TABLE 9 
EXPRESSION OF CD 8 IN SCC - CERVIX 
TYPE 1+(< 25%) 2+(25 -50%) 3+(>50%) 
SCC -Well 
differentiated 
carcinoma 
2 2 5 
SCC - moderately 
differentiated 
carcinoma 
4 2 2 
SCC -Poorly 
differentiated 
carcinoma 
5 1 1 
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TABLE 10 
DISTRIBUTION OF CD 8 IN SCC- CERVIX 
 
TYPE 1+ (negative) 2+& 3+(positive) TOTAL 
SCC - well 
differentiated 
carcinoma 
2 7 9 
SCC- moderately 
differentiated 
carcinoma 
4 4 8 
SCC -poorly 
differentiated 
carcinoma 
5 2 7 
TOTAL 11 13 24 
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TABLE 11 
 
DISTRIBUTION OF CD 8 IN OTHER TYPES OF CANCER 
CERVIX 
 
TYPE 1+ (Negative) 2+& 3+( Positive ) 
Adenocarcinoma 2 1 
Adenosquamous 
carcinoma 
1 1 
Clear cell carcinoma 1 0 
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TABLE 12 
 
CORRELATION OF HLA 1 AND CD 8 IN SQUAMOUS CELL 
CARINOMA 
TYPE HLA 1 + HLA 1 -  CD8 + CD 8 - 
SCC -well 
differentiated 
carcinoma 
7 2 7 2 
SCC- moderately 
differentiated 
carcinoma 
4 4 4 4 
SCC- poorly 
differentiated 
carcinoma 
2 5 2 5 
 
 
TABLE 13 
 
CORRELATION OF HLA 1 AND CD 8 IN OTHER TYPES OF 
CARCINOMA CERVIX 
 
TYPE HLA 1+ HLA - CD 8+ CD 8- 
Adenocarcinoma      1          2         1         2 
Adenosquamous 
carcinoma 
     1          1         1         1 
Clear cell 
carcinoma 
     0          1         0         1 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COLOUR PLATES 
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COLOUR PLATES 
H&E - WELL DIFFERENTIATED SQUAMOUS CELL 
CARCINOMA (10X)  
 
IHC- STRONG EXPRESSION OF HLA 1 IN WELL 
DIFFERENTIATED SCC(40X) 
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IHC - HIGH EXPRESSION  OF  CD 8 IN WELL  
DIFFERENTIATED  SCC (10X) 
 
H & E - POORLY DIFFERENTIATED SCC (40X ) 
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IHC - WEAK EXPRESSION OF HLA 1 IN POORLY 
DIFFERENTIATED SCC (40X) 
 
IHC - LOW EXPRESSION  OF  CD 8  IN  POORLY DIFF. 
SCC(40X) 
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H&E -ADENOCARCINOMA - WELL DIFFERENTIATED 
CARCINOMA (10X ) 
 
IHC - STRONG EXPRESSION  OF HLA 1 IN WELL 
DIFFERENTIATED ADENOCARCINOMA (40X) 
 
 
 
 
 
 64 
 
IHC - HIGH EXPRESSION OF CD 8 IN ADENOCARCINOMA 
(10X) 
 
H&E -CLEAR CELL CARCINOMA (40X ) 
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IHC - WEAK EXPRESSION OF HLA 1 IN CLEAR CELL 
CARCINOMA  (40X) 
 
IHC - LOW EXPRESSION  OF  CD 8  IN  CLEAR  CELL  
CARCINOMA ( 40X ) 
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DISCUSSION 
Carcinoma  cervix  is  the  second  most  common  cancer  among  
the  world 
30,26
 with  increased  mortality  in  around  half  of  the  new  
cases diagnosed  every  year.  
There  is  increasing  incidence  of  invasive  cancer  cervix  and  
deaths  related  to  it  according  to  a  recent  estimate  in  America. 
Greater than 80% of all the cases occur in developing countries.  
The risk  of  cancer  cervix  increases  with  increase  in  age.  
Because  of  the high  prevalence  of  HPV  infection  around  25  years  
of  age,  the carcinoma  incidence  increases  with  age. Due  to  the  
persistent  HPV   infection , the  risk  of  developing  carcinoma  
increases  with  age.
 53
  It  constitutes  about  20%  of  cancer  cervix  at  
the  age  of  >  65  years. 
In the present study, the youngest  age  group  at  which carcinoma  
cervix  was  reported  is  39  years. Its  incidence  is common between  40  
to  50  years. 
Data  from  the  cancer  registries  indicate  that  >  75%  of  
cervical carcinomas  develop  in  women  more  than  35  years  of  age. 
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      Epidemiological  studies suggested  that  high  risk  HPV infection  as   
the  primary risk  factor  for  cancer  cervix.
 32,35
 It  is  well  established  
that  persisting  infections  were  the  most  significant  risk  factor  for  
cancer  cervix.
 36
 Almost  all  cervical  cancers  contain  the  genes  of  
most  common  types  16, 18, 31  and  45  which  are  high  risk  groups.
 
11,35
 HPV 16 was found  to  be  associated  with  tumors  expressing  HLA  
1  antigen.
 56
 Enormous  lines  of  evidence  suggest  that  cell - mediated  
immune  responses  are  very  important  in  controlling  established  HPV  
infections  and  HPV  associated  neoplasms,  especially  in tumor  cell  
clearance.
 34,37
 
 In  patients  with  impaired  cell  mediated  immunity, including  
HIV infected  patients  and  transplant  recipients,  the  prevalence  of  
HPV related diseases  are  higher  in  incidence.
 50
 Infiltrating  CD 4
+
  and  
CD 8 
+
  cells  have been  observed   in  spontaneously  regressing  warts.  
Being  an  important component  of  immune  system, HLA  system  is  
able  to  present  antigenic  peptides  to  antigen - specific  T  
lymphocytes
 59,61
,  they  then  trigger  the  immune  response  to  eliminate  
tumor  specific  proteins.  
The  main  function  of  HLA  1  is  to  combine  with  antigen  and  
forming  HLA -antigen complex  and presenting  them  to  the  cell  
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surface.
 60
 CD 8 
+ 
T cells can  identify  the  complex and  then   be  
activated  and  differentiate  into  cytotoxic  T  cells.
 38
  
These cytotoxic  cells  can  directly  kill  target  cells  via  secreting  
substances  like perforin or  by  inducing  target  cell  apoptosis  through  
Fas / Fas L  way resulting  in  a  special  lethality  for  target  cells.  
Hence  any  modification  in cellular  antigen - presenting system  can   
correlate  with  the  escape  of  CIN  and  carcinoma  in situ  from  
immunological  control  and  then  progress  to  invasive carcinoma.
 39
   
Immune - surveillance  escape  mechanisms  emerges  as  an 
important  step  in  the  progression of  HPV  associated  tumors.
 40,41,42
 
Low  HLA  1  expression  cannot  present  antigenic  peptides  to  the  
cytotoxic  cells.
 43,44
  The   tumor  cells  can  avoid  the  specific  killing  
effects  of  CTL  cells ,  continue  to  progress  and  metastasize. Strong  
tumor  immunity  is  present  in   patients  without  lymph  node  
metastasis.
 45
 
Our  immunohistochemical  study  demonstrated  that  HLA 1 
expression is  statistically  low  in  poorly  differentiated  carcinomas  and   
CD 8 infiltration is also low in poorly differentiated carcinomas. The low  
expression  of  HLA 1
62,63
  and  CD 8  T  cells  in  cervical cancer tissue
 57
  
may  indicate  that  tumor cells exhibit HLA1downregulation, 
23,33
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resultant  loss  of  antigen  presentation  capability and downregulation  of  
endogenous  antigen  processing  machinery for MHC presentation.
 46
 
Michael Campol, et al
13
 studied HLA class 1 antigen loss, tumor 
immune escape and immune selection. 
They have concluded that the outgrowth of a patient's tumor 
reflects immune selection of tumor cells which have acquired escape 
mechanisms from immune recognition.
  
 Louise A . Koopman  et  al
14
  studied  about  Human  Leukocyte 
Antigen  class I  gene  mutations  in  cervical  cancer. 
In  that  they  have  concluded  the  nature  of  nucleotide  
insertions  and  single - base  substitutions  responsible  for  the  complete  
absence  of  HLA  class I  molecules  in  cervical  cancer  in  vitro  and  
ex  vivo. Such tumor - specific mutations may permit the cell to escape 
from HLA class 1 restricted cytotoxic T - cell responses.   
The   present   study  also  states  that  there is  complete  loss  of  
expression  of  HLA -  1  in  poorly  differentiated  cervical squamous cell 
carcinoma.    
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 Jiang  Tao  Fan,  Yan  Liao  et  al
16
  evaluated  the  expression  of  
HLA - 1,  CD 8  and  CD  4  and  their  clinical  significance  in  cervical  
cancer. 
They  observed  that  the diminished  local  expression  of  HLA - 
1,  CD 8  and  CD 4  in  cervical  tissue  may  be  involved  in  the  
occurence  and  progression  of  cervical carcinoma.  
The  present  study  also  observed  that the diminished expression  
of  HLA - 1 and  CD  8 seen  in  the  cervical cancer  tissue. 
 Ekaterina  S. Jordanova  et al
9
  studied  Human  Leukocyte  
antigen  class 1, MHC  class I  chain - related  molecule  A,  and  CD 8
 + 
/ 
Regulatory  T cell ratio:  which  variable  determines  survival  of  
cervical   cancer  patients?  
They  have  concluded  that  weak  HLA-A-MICA   expression 
combined  with  low  CD 8
 + 
 / Treg  ratio  reveals  a  patient  group  with  
the poorest  survival   in  cervical  cancer.  
              The  present  study  shows  that  the  expression  of  HLA - 1  
and  CD  8 is  low  in  poorly  differentiated  carcinoma  cervix. 
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  Robert  P Edwards,   M.D.,  et  al
19
  studied  about  T  
lymphocytes  infiltrating  advanced  grades  of  cervical  neoplasia.  They  
have concluded  that the  CD 8  positive  T cell  infiltrate  far  exceeded  
the  CD 4  positive  cells  in the  invasive ,  but  not  in  the  preinvasive  
lesions, a  finding that  suggests  that  CD 8  cells  are  recruited  
preferentially  to  cervical  lesions with  progression  to  invasion. 
The  present  study  inferred  that  CD 8 T  cells  are  more  
recruited  to  the  invasive  cancer  tissue  site  and  it  is  lost  in  more  
advanced cases. 
               Vivian  M  Spaans  et  al
22
  evaluated  HLA - E  expression  in 
cervical  adenocarcinomas :  association  with  improved  long - term  
survival. 
  They  have  concluded  that  high  expression  of  HLA - E  
occured  in  the majority  of  all  histopathological  subtypes  of  cancer  
cervix ;  especially  in cervical  adenocarcinomas.  High  HLA - E  
expression  in  cervical adenocarcinoma  was  associated  with  improved  
patient  survival.   
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The  present  study  also  demonstrated  that  HLA - 1  is  
expressed  in  all  histopathological  subtypes  and  it  is  more  intensely  
expressed  in  well  differentiated  carcinomas. 
 Debbie  M  Ferns  et  al 
17
 ( 2016 )  evaluated  the  Classical  and  
non - classical  HLA class I  aberrations  in  primary  cervical  squamous  
and adenocarcinomas   and  paired  lymph  node  metastases. 
They  have  concluded  that  the  tumor  immune  escape  variants  
leads  to  metastasis.  Moreover ,  SCC  tumors  shows  downregulation  
of  HLA - 1  A  or total  classical  HLA  in  combination  with  HLA - G 
expression  had  poor prognosis. HLA  expression  is  used  as  a  
biomarker  for  patient  selection for CTL -  and  NK - cell based  
immunotherapeutic  intervention.  
Sine Hadrup et al
31
 studied effector CD 4 and CD 8 T cells and 
their role in the tumor microenvironment. 
Sytse  J . Piersma 
41
 ( 2011 )   studied  Immunosuppressive  tumor  
microenvironment   in  cervical  cancer  patients. 
The final remarks of the study is that  the tumor  microenvironment  
in  cervical  cancer  patients  has  similar  character to  other   types  of  
cancer.  The  immune  escape  variants  can  be  targeted  by  alternative 
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approaches ,  such  as  vaccination  against  epitopes  that  are  associated  
with impaired  antigen  processing.         
 
 Bethwaite  PB  et  al 
51
 studied  infiltration  by  immunocompetent  
cells  in  early  stage  invasive  carcinoma  of  the  uterine  cervix : a  
prognostic  study. 
Present  study  also  concluded  that  there  is  infiltration  of  CD 8 
T lymphocytes  in  the  early  or  well  differentiated  form  of  invasive  
cervical  carcinoma  of  squamous  cell  type. 
 Hildes C et al
66
 studied the  association  between  HLA  expression  
and  infiltration  of  immune  cells   in  cervical  carcinoma. 
They  have  concluded  that   the  tumor  infiltrating  CD 8 +  T  
lymphocytes  correlated  with  monomorphic  HLA  class I  expression.  
This stresses  the  existence  of  HLA - restricted  immune  response  of  
T -  lymphocytes  in  cervical  carcinoma.  
This is in accordance with the present study. 
                           
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
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SUMMARY  
 The  normal  cervix  expresses  MHC  class  1  antigen  on  the  
lower  one  third  to  one  half  of  squamous  epithelium.
 64
 All cells 
express MHC class 1 molecules over their cell surfaces including the 
cervical lining epithelium. 
 In  the  present  study,  well  differentiated  squamous  cell  
carcinoma  recapitulates  partly  the  normal  expression  of  HLA 1 . 
Thus  in  well  differentiated  squamous  cell  carcinoma,  HLA 1  has  
been  expressed  in 7  cases. 
As  the  grade  of  malignancy  increases,  the  expression  of  HLA 
1  is  lost .This  is  exemplified  by  our  study  in  which  5  poorly  
differentiated  squamous  cell  carcinoma  cases  have only < 25%  
positivity  ( 1+ ). 
In  the  present  study,  CD 8  expression  was  found  in  7  cases  
of  well  differentiated  squamous  cell  carcinoma. Thus  it  explains  that  
the  antigen  HLA 1 is  expressed  in  well  differentiated  squamous  cell  
carcinoma  for destruction by  CD8  + T  lymphocytes.  In  parallel,  in  
poorly  differentiated  squamous  cell  carcinoma,  HLA 1  expression  
was  low in 5 cases . In  these 5 cases  of  poorly  differentiated  
squamous  cell  carcinoma ,  CD 8  + lymphocytes  expression  was  also  
low ( <25%  positivity ). 
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CONCLUSION 
Thus in our study , we found that well differentiated carcinomas 
express HLA 1 more efficiently and also we found that good number of 
CD 8 + lymphocytes in well differentiated carcinomas. Also in poorly 
differentiated carcinomas, HLA 1 expression was low with diminished 
number of CD 8 + lymphocytes in the tumor environment and this 
scientifically reconfirms good prognosis in well differentiated carcinomas 
due to HLA 1 expression and cytotoxic destruction of HLA 1 + tumor 
cells by CD 8 + lymphocytes. 
Also we noticed that in our study, even the HLA 1 expression was 
cytoplasmic and not at the membrane level in all carcinomas and further 
studies are required to study the mechanisms involved in the lack of 
expression of HLA 1 at the cell membrane level. Also further studies are 
required for targeting HLA 1 expression and CD 8+ lymphocytes for 
treatment strategies. 
    
         
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURES 
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                                            ANNEXURE I 
PROFORMA 
COIMBATORE MEDICAL COLLEGE 
DEPARTMENT OF PATHOLOGY 
COIMBATORE 
Particulars of the patient: 
Name  :                                         IP/OP NUMBER: 
Age:                                              Ward number: 
Sex:                                                occupation:        
Address: 
Presenting complaints: 
Change  in  bowel  habits 
Blood  in  the  stool 
Loss  of  weight,  loss  of  appetite 
Family history: 
Malignancy +/- 
Personal history:smoker 
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GENERAL PHYSICAL EXAMINATION: 
Built:                                                               Febrile : 
Nourishment :                                                 Pallor: 
Conscious :                                                    Jaundice: 
Weight :                                                        Cyanosis: 
Pulse rate:                                                     Clubbing: 
Respiratory rate :                                          Lymphadenopathy: 
SYSTEMIC EXAMINATION: 
RS:                                                P/A: 
CVS:                                              CNS: 
CLINICAL DIAGNOSIS: 
RADIOLOGICAL FINDINGS: 
USG: 
CT: 
MRI: 
MICROSCOPIC FINDINGS: 
Histopathological diagnosis: 
FINAL DIAGNOSIS: 
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ANNEXURE  II 
ABBREVIATIONS 
1. HLA - Human Leukocyte  Antigen 
2. MHC - Major Histocompatability Complex 
3. CD - Cluster  Differentiation 
4. PAP – Papanicolaou 
5. HPV -Human Papilloma Virus 
6. HSV - Herpes S implex Virus 
7. IUCD - Intrauterine Contraceptive device 
8. DPX - Di- N-Butyle Phthalate in Xylene 
9. WHO- World Health Organisation 
10. CIN - Cervical Intraepithelial Neoplasia 
11. ISGYP - International  Society of Gynaecological Pathologist 
12. LSIL - Low grade Squamous Intraepithelial Lesion 
13. HSIL - High grade Squamous Intraepithelial Lesion 
14. HIV - Human Immunodeficiency Virus 
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15. NOS - Not Otherwise Specified 
16. CTL - Cytotoxic Lymphocytes 
17.  NK - Natural Killer cells 
18. SCC -Squamous Cell Carcinoma 
19. AIS - Adenocarcinoma in Situ.
 80 
 
ANNEXURE III 
MASTER CHART 
Sl. 
No 
AGE 
HPE 
NO 
IP NO CLINICALDIAGNOSIS 
HISTOPATHOLOGICAL  
DIAGNOSIS 
GRADE TYPE IHC - HLA1 IHC - CD8 
  
      
        
1+ 
(negative) 
2+  &3+ 
positive 
1+                                                    
(negative) 
2+ & 3+
(positive ) 
1 
48/ F 2175/16 88369 
?carcinoma  cervix Squamous cell carcinoma Well differentiated 
Large cell 
keratinising 
- + - + 
2 60/F 4273/16 78384 Bleeding P/V Clear cell carcinoma     + - + - 
3 
45/F 30/17 886465 
?carcinoma  cervix Squamous cell carcinoma 
Poorly 
differentiated Non Keratinizing 
+ - + - 
4 
51/F 31/17 7303 
?carcinoma  cervix Squamous cell carcinoma 
Poorly 
differentiated Non Keratinizing 
+ - + - 
5 65/F 95/17 909437 ?carcinoma  cervix Squamous cell carcinoma Well differentiated Keratinizing - + - + 
6 48/F 121/17 910926 ViA/ ViLI positive Squamous cell carcinoma Well differentiated Keratinizing - + - + 
7 
60/F 138/17 858680 
?carcinoma  cervix Squamous cell carcinoma 
Poorly 
differentiated Non Keratinizing 
+ - + - 
8 
59/F 261/17 941077 
?Carcinoma  cervix Squamous cell carcinoma 
Poorly 
differentiated Non Keratinizing 
+ - +         - 
9 39/F 291/17 951955 ViA/ ViLI positive Squamous cell carcinoma Well differentiated Keratinizing -           - - + 
10 
85/F 410/17 16830 
Bleeding P/V Squamous cell carcinoma Moderately diff. 
Large cell 
Keratinising 
-          + - + 
11 45/F 423/17 981215 ViA/ ViLI positive Squamous cell carcinoma Moderately diff. Keratinizing -          + - + 
12 56/F 344/17 13113 Bleeding P/V Squamous cell carcinoma Well differentiated Keratinizing -          + - + 
13 
41/F 553/17 1008875 
?carcinoma  cervix Squamous cell carcinoma 
Poorly 
differentiated Non Keratinizing 
+           - + - 
14 
60/F 683/17 1030105 
?carcinoma  cervix Squamous cell carcinoma 
Poorly 
differentiated Non Keratinizing 
+           - + - 
15 55/F 751/17 24819 Bleeding P/V Squamous cell carcinoma Moderately diff. Non Keratinizing +           - + - 
16 45/F 752/17 1041548 ViA/ ViLI positive Adenosquamous Ca Moderately diff.   -          + - + 
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Sl. 
No 
AGE 
HPE 
NO 
IP NO CLINICALDIAGNOSIS 
HISTOPATHOLOGICAL  
DIAGNOSIS 
GRADE TYPE IHC - HLA1 IHC - CD8 
17 
51/F 822/17 30762 
ViA/ ViLI positive Squamous cell carcinoma Moderately diff. Non Keratinizing 
- + - + 
18 
70/F 901/17 1071573 
Bleeding P/V Squamous cell carcinoma 
Poorly 
differentiated Non Keratinizing 
        + - + - 
19 
68/F 60/17 901542 
?carcinoma  cervix Adenosquamous Ca Moderately diff.   
         - + - + 
20 
46/F 139/17 918914 
ViA/ ViLI positive Squamous cell carcinoma Moderately diff. Non Keratinizing 
        + - + - 
21 
47/F 717/17 24819 
ViA/ ViLI positive Adenocarcinoma Well differentiated   
- + - + 
22 
42/F 46/17 360 
ViA/ ViLI positive Adenocarcinoma Moderately diff.   
+ - + - 
23 
55/F 1055/17 1099715 
?carcinoma  cervix Adenosquamous Ca     
- + -         + 
24 
46/F 1056/17 44873 
ViA/ ViLI positive Squamous cell carcinoma Moderately diff. Non Keratinizing 
- + - + 
25 
70/F 1089/17 46651 
Bleeding P/V Squamous cell carcinoma Moderately diff. Non Keratinizing 
+ -        + - 
26 
68/F 1106/17 442127 
Bleeding P/V Squamous cell carcinoma Well differentiated Keratinizing 
- + - + 
27 
50/F 1108/17 1108575 
?carcinoma  cervix Squamous cell carcinoma Moderately diff. Non Keratinizing 
+ - + - 
28 
65/F 1294/17 52282 
?carcinoma  cervix Squamous cell carcinoma Well differentiated Keratinizing 
- + - + 
29 
70/F 1306/17 81122 
?carcinoma  cervix Squamous cell carcinoma Well differentiated Keratinizing 
- + - + 
30 
55/F 1435/17 87007 
Growth cervix Squamous cell carcinoma Well differentiated Keratinizing 
- + - + 
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